Isogenica Ltd has entered into a new research collaboration with AstraZeneca, an announcement from the company has said.

Under the collaboration, Isogenica's CIS display technology will be used for the discovery of peptides, which are specific for, and biologically active against, targets provided by AstraZeneca.

The collaboration builds upon a successful pilot study that was initiated by both parties in 2004. Isogenica's CIS display technology can rapidly identify peptides and polypeptides that bind with high affinity and fine specificity to any given molecular target. CIS display can be widely applied to the drug discovery and development process as well as to the discovery and development of non-therapeutic products.

Chief executive of Isogenica Dr Kevin FitzGerald, said: “We are very pleased to welcome back AstraZeneca as a returning customer. We look forward to re-establishing the excellent working relationship that was a key feature of our previous collaboration.”

Vice president of Discovery Enabling Capabilities and Sciences at AstraZeneca Dr Paul Leff, added that Isogenica's technology “can provide significant opportunities within the lead generation and target validation phases of the drug discovery process.”

© Crimson Business Ltd. 2006